Fredag 2 Januari | 10:06:05 Europe / Stockholm
Svenska | English

BioStock

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

OncoZenge advances BupiZenge with CTA submission and 9,1 MSEK funding tranche
2025-12-19 12:52:00

OncoZenge is ending the year with a dual milestone. The company has submitted the Clinical Trial Application to the EMA for the pivotal phase III trial of BupiZenge. This operational achievement immediately triggered the third tranche of the company’s investment agreement, securing approximately 9,1 MSEK from strategic partner Sichuan Yangtian Bio-Pharmaceutical.

Read the full article at biostock.se:

OncoZenge advances BupiZenge with submitted CTA application and financing of SEK 9,1 million
 
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter 
Follow BioStock on social media: LinkedIn and Facebook!  
 
About BioStock 
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.  
BioStock – Connecting Innovation & Capital. 

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden